Related references
Note: Only part of the references are listed.Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
Anish Thomas et al.
CANCER CELL (2021)
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
Nitin Roper et al.
NATURE COMMUNICATIONS (2021)
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate
Abbie S. Ireland et al.
CANCER CELL (2020)
The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report
Sarah M. Pearsall et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization
Marina K. Baine et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures
Camille Tlemsani et al.
CELL REPORTS (2020)
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity
Kathryn L. Simpson et al.
NATURE CANCER (2020)
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
C. Allison Stewart et al.
NATURE CANCER (2020)
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Anish Thomas et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Yu-Han Huang et al.
GENES & DEVELOPMENT (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes
Wei Zhang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
Prevalence and patterns of tobacco smoking among Chinese adult men and women: findings of the 2010 national smoking survey
Shiwei Liu et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer
Karen McColl et al.
ONCOTARGET (2017)
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
C. Allison Stewart et al.
ONCOTARGET (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
Small-cell lung cancer: what we know, what we need to know and the path forward
Adi F. Gazdar et al.
NATURE REVIEWS CANCER (2017)
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
Triparna Sen et al.
CANCER RESEARCH (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Gurkan Mollaoglu et al.
CANCER CELL (2017)
YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer
Masafumi Horie et al.
CANCER SCIENCE (2016)
ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs
Mark D. Borromeo et al.
CELL REPORTS (2016)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer
Martin L. Sos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
T. John et al.
ONCOGENE (2009)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
